Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns. 1976

J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic

Gram-negative bacilli isolated from clinical specimens submitted for culture in two Paris hospitals during 1974 were studied for susceptibility to six currently used aminoglycosides: kanamycin, neomycin, paromomycin, lividomycin, gentamicin, and tobramycin. Resistance patterns of strains of various species including those of Enterobacteriaceae, Pseudomonas, and Moraxella were determined, and the strains were grouped into eight resistance "phenotypes." In comparative studies of 807 strains belonging to different phenotypes, amikacin was markedly more active than any of the six other antibiotics; at concentrations of less than or equal to 4 mug/ml, it inhibited about 88% of the strains, including those resistant to gentamicin and tobramycin. Some amikacin-resistant strains were found among different species. The mechanism of resistance to amikacin of strains of Serratia and Moraxella group II was related to an N-acetylating enzyme. Amikacin can be expected to be useful as an alternative treatment of infections due to gram-negative bacilli sensitive to aminoglycosides and also, more particularly, for the treatment of patients infected with multiresistant strains.

UI MeSH Term Description Entries
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D009016 Moraxella A genus of gram-negative, aerobic bacteria occurring as rods (subgenus Moraxella) or cocci (subgenus Branhamella). Its organisms are parasitic on the mucous membranes of humans and other warm-blooded animals.
D009355 Neomycin Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis. Fradiomycin Sulfate,Neomycin Palmitate,Neomycin Sulfate
D010303 Paromomycin An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES. Aminosidine,Catenulin,Estomycin,Hydroxymycin,Neomycin E,Gabbromycin,Humatin,Paramomycin,Paromomycin I,Paromomycin Phosphate,Paromomycin Sulfate,Paromomycin Sulfate (1:1),Paromomycin Sulfate (2:5),Paromomycin, beta-D-Glucopyranosyl-Isomer,Paromomycin, beta D Glucopyranosyl Isomer,beta-D-Glucopyranosyl-Isomer Paromomycin
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004755 Enterobacteriaceae A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock. Coliform Bacilli,Enterobacteria,Ewingella,Leclercia,Paracolobactrum,Sodalis
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D000583 Amikacin A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics. A.M.K,Amikacin Sulfate,Amikacina Medical,Amikacina Normon,Amikafur,Amikalem,Amikason's,Amikayect,Amikin,Amiklin,Amukin,BB-K 8,BB-K8,Biclin,Biklin,Gamikal,Kanbine,Oprad,Yectamid,BB K 8,BB K8,BBK 8,BBK8,Medical, Amikacina,Normon, Amikacina,Sulfate, Amikacin
D000617 Aminoglycosides Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. Aminoglycoside

Related Publications

J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
September 1982, JAMA,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
February 1985, The Journal of infectious diseases,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
January 1979, Bollettino dell'Istituto sieroterapico milanese,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
January 1989, Scandinavian journal of infectious diseases,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
June 1977, The American journal of medicine,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
May 1981, Canadian Medical Association journal,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
January 1977, The American journal of the medical sciences,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
June 1975, The Japanese journal of antibiotics,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
March 1980, The Journal of infectious diseases,
J F Acar, and J L Witchitz, and F Goldstein, and J N Talbot, and F Le Goffic
January 1987, Drugs under experimental and clinical research,
Copied contents to your clipboard!